Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.41 |
| ▸ | DNM2 | P50570 | 3/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 4/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.38 |
| ▸ | MERTK | Q12866 | 4/20 | 0.38 |
| ▸ | GAS6 | Q14393 | 4/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378721 | 0.81 | KCNH3 (0.41) | KMT2AABL1KCNH3DNM2FLT3 | |
| SCHEMBL3455242 | 0.79 | ULK1 (0.41) | KMT2AABL1KCNH3DNM2FLT3 | |
| SCHEMBL28413722 | 0.79 | KMT2A (0.42) | KMT2AKCNH3DNM2STK17AFLT3 | |
| SCHEMBL5975211 | 0.76 | L3MBTL1 (0.52) | KMT2ASTK17AEGFRFGFR1L3MBTL1 | |
| SCHEMBL4188949 | 0.75 | KMT2A (0.47) | KMT2AABL1STK17ASTK17BKDM4E | |
| SCHEMBL11173788 | 0.72 | KCNH3 (0.44) | KMT2AKCNH3DNM2NPSR1 | |
| SCHEMBL2514104 | 0.72 | KMT2A (0.55) | KMT2AKCNH3DNM2NPSR1 | |
| SCHEMBL27527903 | 0.72 | LRRK2 (0.41) | KMT2AEGFRFGFR1 | |
| SCHEMBL516082 | 0.72 | KCNH3 (0.54) | KMT2AKCNH3DNM2NPSR1 | |
| SCHEMBL20641881 | 0.72 | KMT2A (0.39) | KMT2AKCNH3DNM2FLT3TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | KMT2A 4408/4885ABL1 370/4885KCNH3 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.